AVR's Principal Activity is the sale, distribution, maintenance and implementation of infusion solutions to major hospitals and health facilities in Australia and New Zealand; The manufacturing, sale and distribution of proprietary ADAPT regenerative tissue products globally; and Continued research and development of regenerative medicine and immunotherapies.
Last (Price) | |
Change | 0.00 (0.00) |
Bid / Ask | - |
Volume | |
Volume (4w avg) | |
Turnover | |
Open | |
Day Range | - |
VWAP | |
Prev Close | |
Last Trade |
1 Week | |
1 Month | |
2021 YTD | |
1 Year | |
vs Sector (1yr) | +37.00% |
vs ASX 200 (1yr) | -0.40% |
Market Capitalisation | |
ASX Rank | 1204 of 2,564 |
Sector Rank | 102 of 177 |
Date | Heading | Pages | File Size | Time |
---|---|---|---|---|
Anteris Technologies Ltd (AVR, formerly Admedus Ltd) is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Its focus is on investing in and developing next generation technologies with world class partners and acquiring strategic assets to grow product and service offerings.
Incorporated bioMD Limited was incorporated in June 1999 in Western Australia. Code changed to Allied Healthcare Group Ltd (AHZ) on 30/06/2011
Head Office | Toowong QLD 4066 |
Website | www.anteristech.com |
Registry | Computershare |
Auditor | HLB Mann Judd |
Date Listed | 24 Mar 2004 |
Date | Event |
---|---|
14/05/2021 | AGM |
19/08/2021 | Report (Interim) |
17/02/2022 | Report (Prelim) |
14/04/2022 | Report (Annual) |
See Upcoming Dividends for all ASX companies.
AVR directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
The current holdings of AVR directors.
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
Name | Last Notice | Total Shares | Shares Held (%) |
---|---|---|---|
Mercer Street Global Opportunity Fund LLC | 20/01/2021 | 341,545 | 5.20 |
Star Bright Holding Limited | 14/07/2020 | 730,192 | 12.35 |
Sio Partners LP | 20/01/2021 | 1,311,079 | 19.96 |
12 month transaction history compiled from ASX announcements.
Date | Name | Bought | Previous % | New % |
---|---|---|---|---|
20-01-21 | Mercer Street Global Opportunity Fund LLC | 341,545 | -- | 5.20 |
14-07-20 | Constellation Immunotherapy Limited | 326,951 | -- | 5.53 |
12 month transaction history compiled from ASX announcements.
Date | Name | Sold | Previous % | New % |
---|---|---|---|---|
20-01-21 | Sio Partners LP | 129,809,772 | 22.20 | 20.0 |
20-07-20 | Constellation Immunotherapy Limited | 326,951 | 5.53 | -- |
14-07-20 | Star Bright Holding Limited | 546,963 | 21.61 | 12.3 |
18-06-20 | Star Bright Holding Limited | 132,176,280 | 22.62 | 21.6 |
Date | Close | Change | %Chg | Open | High | Low | Volume | Turnover |
---|---|---|---|---|---|---|---|---|
Year | Closing Price | Last Trade |
---|---|---|
2020 | $4.90 | 30 June |
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.